Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma
Authors:
- 1 August 2008
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 159 (2) , 387-393
Abstract
Photodynamic therapy (PDT) involves the activation of a photosensitizer by visible light to produce activated oxygen species within target cells, resulting in their destruction. Evidence-based guidelines support the efficacy of PDT using topical 5-aminolaevulinic acid (ALA-PDT) in actinic keratoses, Bowen disease and basal cell carcinoma (BCC). Efficacy for nodular BCC appears inferior to that for superficial BCC unless prior debulking or repeat treatments are performed. Objectives The aim of this study was to assess the safety and efficacy of adding a novel iron-chelating agent, CP94 (1,2-diethyl-3-hydroxypyridin-4-one hydrochloride), to topical ALA, to temporarily increase the accumulation of the photosensitizer in the tumour. A mixed topical formulation of ALA + increasing concentrations of CP94 was used to carry out PDT on previously biopsied nodular BCC with no prior lesion preparation using standard light delivery. The area was assessed clinically and surgically excised 6 weeks later for histological examination. Enhanced PDT using 40% CP94 resulted in significantly greater clearance rates in nodular BCC than with ALA-PDT alone, in our protocol of single-treatment PDT with no lesion preparation. The results of this study demonstrate the safe and effective use of an enhanced ALA-PDT protocol for nodular BCC using CP94, with no adverse reactions to this modification. This is the first time this formulation has been used in patients. This formulation is now the focus of further study.Keywords
This publication has 23 references indexed in Scilit:
- Direct Comparison of δ-Aminolevulinic Acid and Methyl-Aminolevulinate-Derived Protoporphyrin IX Accumulations Potentiated by Desferrioxamine or the Novel Hydroxypyridinone Iron Chelator CP94 in Cultured Human CellsPhotochemistry and Photobiology, 2007
- Photodynamic Therapy Using Topical Methyl Aminolevulinate vs Surgeryfor Nodular Basal Cell CarcinomaArchives of Dermatology, 2004
- Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology GroupBritish Journal of Dermatology, 2002
- SHORT COMMUNICATIONPhotodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking techniqueBritish Journal of Dermatology, 2000
- Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agentsBritish Journal of Cancer, 1998
- Modified Topical Photodynamic Therapy of Superficial Skin Tumors, Utilizing Aminolevulinic Acid, Penetration Enhancers, Red Light, and HypertherntiaDermatologic Surgery, 1998
- 5-Aminolevulinic acid-based photodynamic therapyCancer, 1997
- Photodynamic therapy of non-melanoma malignant tumours of the skin using topical δ-amino levulinic acid sensitization and laser irradiationBritish Journal of Dermatology, 1994
- HOW DOES PHOTODYNAMIC THERAPY WORK?Photochemistry and Photobiology, 1992
- Photodynamic therapy with endogenous protoporphyrinJournal of Photochemistry and Photobiology B: Biology, 1990